Zhenjun Li, Liangcheng Lv, Xiaoyu Yao, Zhiwei Feng, Yan Xie, Kecheng Li, Feifei Qi, Mei Yang, Jingwen Wang, Tao Pan, Xinghua Li, Haiyan Chen, Jing Wang, Yanping Ding, Jun Zhu, Yuqin Song, Xiaomin Wang*, Ning Ding*. ITK-targeted immune remodeling enhanced the efficacy of anti-CD19 CAR-T cell therapy.,Cell Death Discov.,12(1):131

Jiaowu Cao, Dingyao Hu, Hui Yu, Yan Xie, Lan Mi, Yingying Ye, Mi Deng, Weimin Zhang, Miaomiao Li, Dedao Wang, Fei Qi, Jiajin Wu, Yuqin Song*, Jun Zhu*, Ning Ding*. Interleukin-2-inducible T-cell kinase inhibition to block NF-κB signaling exerts anti-tumor effects and enhances chemotherapy in NK/T-cell lymphoma.,Cancer Lett.,618:217602

Can Zhu, Zimo Yang, Yuxiao Zhang, Zhenjun Li, Guangchen Li, Bing Yang, Na Kang, Jingwen Wang, Yonghui Sun, Ning Ding*, Yu Rao*, Wanli Liu*,Cell Discovery,2024 Aug 6;10(1):82

Li M, Ding N, Mi L, Shi Y, Du X, Yi Y, Yang L, Liu W, Zhu J. Liquid biopsy in diffuse large B-cell lymphoma: utility in cell origin determination and survival prediction in Chinese patients.,Leuk Lymphoma,63(3):608-617

淋巴瘤临床转化研究

ITK抑制剂逆转复发难治外周T细胞淋巴瘤患者T细胞耗竭的机制研究, 课题负责人, 2025.1.1～2028.12.31, 国家自然科学基金

智能PROTAC脂质纳米药物抗肿瘤效果及生物安全性评估, 课题负责人, 2022.10.1～2026.10.31, 北京市自然科学基金重点研究专项

PAK1诱导套细胞淋巴瘤发生伊布替尼耐药的分子机制研究, 课题负责人, 2020.1.1～2023.12.31, 国家自然科学基金

Itk抑制剂CPI-818联合CD19-CAR-T抗B细胞淋巴瘤的临床前研究, 课题负责人, 2023.12.1～2024.12.31, 横向课题